爱尔兰爵士制药的去纤苷价格

(Defibrotide) is currently recognized as the most promising new drug for the treatment of HVOD after HSCT. Based on its anticoagulant, fibrinolysis-promoting, and anti-inflammatory effects, foreign researchers have explored its application in the treatment of HVOD after HSCT. This study included 19 sHVOD patients. The dose of defibrotide is 5 to 60 mg/kg per day, intravenous infusion, and the median use time is 15 days (2 to 61 days). The results showed that 42% of patients achieved complete remission (CR), and the overall survival (OS) rate 100 days after transplantation reached 32%, and patients could tolerate defibrotide well.

On October 18, 2013, defibrotide sodium (defibrotide) was approved for marketing by the EU EMA and received orphan drug designation. At the end of March 2016, the drug was approved by the FDA for official marketing, providing another new choice and opportunity for the treatment of many patients. Many patients must have asked: What is the price of defibrinoside from Jazz Pharmaceuticals in Ireland? Let us find out below!

According to Medical Companion Travel, one tube of Defibrotide, a drug owned by Irish Jazz Pharmaceuticals, has a specification of 200 mg, and each tube sells for about $22,000. The price will also change as the exchange rate fluctuates, so please consult Medical Travel for the specific price. Of course, patients who want to purchase defibrotide can also use Medical Companion Travel to obtain drug purchase channels overseas.

Jazz Pharmaceuticals is a specialty biopharmaceutical company that, since its founding in 2003, has built a commercial and development organization and assembled products and product candidates that currently include two marketed products and product candidates in various stages of clinical development. It is mainly engaged in the participation, research and development and sales of various medical drugs in the United States, Europe and internationally. Jazz Pharmaceuticals has many products, including (Defibrotide).

Recommended hot articles: /newsDetail/90909.html